Therapeutic targets for multiple sclerosis

Drugs of the Future

Volumn 34, Issue 5, 2009, Pages 405-417

  Sorbera, L A ^a   Dulsat, C ^a   Rosa, E ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 2 [2 [4 (3 BENZYLOXYPHENYLTHIO) 2 CHLOROPHENYL]ETHYL] 1,3 PROPANEDIOL; ABS 75; ADENOSINE DEAMINASE; ALEMTUZUMAB; AMPA RECEPTOR; ANTIINFECTIVE AGENT; ATORVASTATIN; AZD 5904; BAF 312; BETA INTERFERON; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; CGEN 54; CHR 1103; CLADRIBINE; COG 112; CS 0777; DACLIZUMAB; DRONABINOL; FIRATEGRAST; FLUPIRTINE MALEATE; GLATIRAMER; GRC 4039; HT 1001; IMMUNOMODULATING AGENT; INCB 8696; MLN 0415; MT 203; OCRELIZUMAB; OFATUMUMAB; ONO 4641; OPL CCL2 LPM; PAP 1; PS 031291; RITUXIMAB; SHK 186; SIMVASTATIN; TERIFLUNOMIDE; TRX 1; TV 1102; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CHEMOTAXIS; CLINICAL TRIAL; DISEASE COURSE; DRUG APPROVAL; HUMAN; LYMPHOCYTIC INFILTRATION; MULTIPLE SCLEROSIS; NEUROPROTECTION; REMYELINIZATION; REVIEW;

EID: 76649107918     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.05.1364290     Document Type: Review

References (95)

1. Prous Science Integrity Disease Briefings: Multiple Sclerosis (online publication). Updated 2009.
2. Compston, A., Coles, A. Multiple sclerosis. Lancet 2008, 372(9648): 1502-17.
3. Noseworthy, J.H., Lucchinetti, C., Rodriguez, M., Weinshenker, B.G. Multiple sclerosis. N Engl J Med 2000, 343(13): 938-52.
4. Kobelt, G., Pugliatti, M. Cost of multiple sclerosis in Europe. Eur J Neurol 2005, 12(Suppl. 1): 63-7.
5. Miller, D.H., Leary, S.M. Primary-progressive multiple sclerosis. Lancet Neurol 2007, 6(10): 903-12.
6. Frohman, E.M., Filippi, M., Stuve, O. et al. Characterizing the mechanisms of progression in multiple sclerosis: Evidence and new hypotheses for future directions. Arch Neurol 2005, 62(9): 1345-56.
7. Ramagopalan, S.V., Valdar, W., Dyment, D.A. et al.; Canadian Collaborative Study Group. Association of infectious mononucleosis with multiple sclerosis. A population-based study. Neuroepidemiology 2009, 22(4): 257-62.
8. Alvarez-Lafuente, R., Garcia-Montojo, M., De Las Heras, V., Dominguez-Mozo, M.I., Bartolome, M., Benito-Martin, M.S., Arroyo, R. Herpesviruses and human endogenous retroviral sequences in the cerebrospinal fluid of multiple sclerosis patients. Mult Scler 2008 ,14(5): 595-601.
9. Lünemann, J.D., Münz, C. EBV in MS: Guilty by association? Trends Immunol 2009, Epub ahead of print.
10. Irvine, K.A., Blakemore, W.F. Remyelination protects axons from demyelination-associated axon degeneration. Brain 2008, 131(Pt. 6): 1464-77.
11. Frohman, E.M., Racke, M.K., Raine, C.S. Multiple sclerosis -The plaque and its pathogenesis. N Engl J Med 2006, 354(9): 942-55.
12. Zozulya, A.L., Wiendl, H. The role of regulatory T cells in multiple sclerosis. Nat Clin Pract Neurol 2008, 4(7): 384-98.
13. Somers, K., Govarts, C., Stinissen, P., Somers, V. Multiplexing approaches for autoantibody profiling in multiple sclerosis. Autoimmun Rev 2009, Epub ahead of print.
14. Anolik, J.H., Looney, R.J., Lund, F.E., Randall, T.D., Sanz, I. Insights into the heterogeneity of human B cells: Diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res 2009, Epub ahead of print.
15. Lublin, F. History of modern multiple sclerosis therapy. J Neurol 2005, 252(Suppl. 3): iii3-iii9.
16. Palmer, A.M. Pharmacotherapy for multiple sclerosis: Progress and prospects. Curr Opin Investig Drugs 2009, 10(5): 407-17.
17. Pluchino, S., Zanotti, L., Brini, E., Ferrari, S., Martino, G. Regeneration and repair in multiple sclerosis: The role of cell transplantation. Neurosci Lett 2009, 456(3): 101-6; 18.
18. Weiner, H.L. The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease? Ann Neurol 2009, 65(3): 239-48.
19. Meuth, S.G., Kleinschnitz, C., Wiendl, H. Recent clinical trials and future therapies. J Neurol 2008, 255(Suppl. 6): 93-6.
20. Stangel, M. Neuroprotection and neuroregeneration in multiple sclerosis. J Neurol 2008, 255(Suppl. 6): 77-81.
21. Amorini, A.M., Petzold, A., Tavazzi, B. et al. Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin Biochem 2009, Epub ahead of print.
22. Mahad, D., Lassmann, H., Turnbull, D. Review: Mitochondria and disease progression in multiple sclerosis. Neuropathol Appl Neurobiol 2008, 34(6): 577-89.
23. Sipe, J.C. Cladribine for multiple sclerosis: Review and current status. Expert Rev Neurother 2005, 5(6): 721-7.
24. Centonze, D., Muzio, L., Rossi, S. et al. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci 2009, 29(11): 3442-52.
25. Trapp, B.D., Stys, P.K. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009, 8(3): 280-91.
26. Szénési, G., Vegh, M., Szabo, G. et al. 2,3-Benzodiazepine-type AMPA receptor antagonists and their neuroprotective effects. Neurochem Int 2008, 52(1-2): 166-83.
27. Basavarajappa, B.S., Nixon, R.A., Arancio, O. Endocannabinoid system: Emerging role from neurodevelopment to neurodegeneration. Mini Rev Med Chem 2009, 9(4): 448-62.
28. Pertwee, R.G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009, 156(3): 397-411.
29. Palazuelos, J., Davoust, N., Julien, B. et al. The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: Involvement in the pathogenesis of an animal model of multiple sclerosis. J Biol Chem 2008, 283(19): 13320-9.
30. Malfitano, A.M., Proto, M.C., Bifulco, M. Cannobinoids in the management of spasticity associated with multiple sclerosis. Neuropsychiatr Dis Treat 2008, 4(5): 847-53.
31. Oh, U., Blevins, G., Griffith, C. et al. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol 2009, 66(4): 471-9.
32. Korn, T. Pathophysiology of multiple sclerosis. J Neurol 2008, 255(Suppl. 6): 2-6.
33. Lopez-Diego, R.S., Weiner, H.L. Novel therapeutic strategies for multiple sclerosis - A multifaceted adversary. Nat Rev Drug Discov 2008, 7(11): 909-25.
34. Rommer, P.S., Stüve, O., Goertsches, R., Mix, E., Zettl, U.K. Monoclonal antibodies in the therapy of multiple sclerosis: An overview. J Neurol 2008, 255(Suppl. 6): 28-35.
35. Dalakas, M.C. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 2008, 4(10): 557-67.
36. Waubant, E. Spotlight on anti-CD20. Int MS J 2008, 15(1): 19-25.
37. Coles, A.J., Compston, D.A., Selmaj, K.W. et al.; CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-la in early multiple sclerosis. N Engl J Med 2008, 359(17): 1786-801.
38. Muraro, P.A., Bielekova, B. Emerging therapies for multiple sclerosis. Neurotherapeutics 2007, 4(4): 676-92.
39. Jones, J.L., Coles, A.J. Campath-1H treatment of multiple sclerosis. Neurodegener Dis 2008, 5(1): 27-31.
40. Merritt, J.R., Liu, J., Quadros, E. et al. Novel pyrrolidine ureas as C-C chemokine receptor 1 (CCR1) antagonists. J Med Chem 2009, Epub ahead of print.
41. Savarin-Vuaillat, C., Ransohoff, R.M. Chemokines and chemokine receptors in neurological disease: Raise, retain, or reduce? Neurotherapeutics 2007, 4(4): 590-601.
42. Szczuci?ski, A., Losy, J. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol Scand 2007, 115(3): 137-46.
43. Kalinowska, A., Losy, J. Investigational C-C chemokine receptor 2 antagonists for the treatment of autoimmune diseases. Expert Opin Investig Drugs 2008, 17(9): 1267-79.
44. Fox, R.J., Kivisakk, P., Fisher, E., Tucky, B., Lee, J.C., Rudick, R.A., Ransohoff, R.M. Multiple sclerosis: Chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury. Mult Scler 2008, 14(8): 1036-43.
45. Merrill, J.E., Hanak, S., Pu, S.F. et al. Teriflunomide reduces behavioral, electrophysiological, and histopothological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J Neurol 2009, 256(1): 89-103.
46. Walse, B., Dufe, V.T., Svensson, B. et al. The structures of human dihydroorotate dehydrogenase with and without inhibitor reveal conformational flexibility in the inhibitor and substrate binding sites. Biochemistry 2008, 47(34): 8929-36.
47. King, I.L., Dickendesher, T.L., Segal, B.M. Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood 2009, 113(14): 3190-7.
48. Uemura, Y., Ohno, H., Ohzeki, Y., Takanashi, H., Murooka, H., Kubo, K., Serizawa, I. The selective M-CSF receptor tyrosine kinase inhibitor Ki20227 suppresses experimental autoimmune encephalomyelitis. J Neuroimmunol 2008, 195(1-2): 73-80.
49. Zaheer, A., Zaheer, S., Sahu, S.K., Knight, S., Khosravi, H., Mathur, S.N., Lim, R. A novel role of glia maturation factor: Induction of granulocytemacrophage colony-stimulating factor and pro-inflammatory cytokines. J Neurachem 2007, 101(2): 364-76.
50. Paintlia, A.S., Paintlia, M.K., Singh, I., Skoff, R.B., Singh, A.K. Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis. Glia 2009, 57(2): 182-93.
51. Paintlia, A.S., Paintlia, M.K., Singh, I., Singh, A.K. Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis. Exp Neurol 2008, 214(2): 168-80.
52. Bifulco, M., Malfitano, A.M., Marasco, G. Potential therapeutic role of statins in neurological disorders. Expert Rev Neurother 2008, 8(5): 827-37.
53. Zipp, F., Waiczies, S., Aktas, O. et al. Impact of HMG-CoA reductase inhibition on brain pathology. Trends Pharmacol Sci 2007, 28(7): 342-9.
54. Reiss, A.B., Wirkowski, E. Role of HMG-CoA reductase inhibitors in neurological disorders: Progress to date. Drugs 2007, 67(15): 2111-20.
55. Wang, Y., Feng, D., Liu, G., Luo, Q., Xu, Y., Lin, S., Fei, J., Xu, L. Gamma-aminobutyric acid transporter 1 negatively regulates T cell-mediated immune responses and ameliorates autoimmune inflammation in the CNS. J Immunol 2008, 181(12): 8226-36.
56. Sun, X.F., Zhang, H. NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol 2007, 22(12): 1387-98.
57. Curran, N.M., Griffin, B.D., O'Toole, D., Brady, K.J., Fitzgerald, S.N., Moynagh, P.N. The synthetic cannabinoid R(+)WIN 55,212-2 inhibits the interleukin-1 signaling pathway in human- astrocytes in a cannabinoid receptor-independent manner. J Biol Chem 2005, 280(43): 35797-806.
58. Tsunoda, I., Terry, E.J., Marble, B.J., Lazarides, E., Woods, C., Fujinami, R.S. Modulation of experimental autoimmune encephalomyelitis by VLA-2 blockade. Brain Pathol 2007, 17(1): 45-55.
59. Stüve, O. The effects of natalizumab on the innate and adaptive immune system in the central nervous system. J Neurol Sci 2008, 274(1-2): 39-41.
60. Zohren, F., Toutzaris, D., Klärner, V., Hartung, H.P., Kieseier, B., Haas, R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 2008, 111(7): 3893-5.
61. Davenport, R.J., Munday, J.R. Alpha4-integrin antagonism - An effective approach for the treatment of inflammatory diseases? Drug Discov Today 2007, 12(13-14): 569-76.
62. Alcina, A., Fedetz, M., Ndagire, D. et al. IL2RA/CD25 gene polymorphisms: Uneven association with multiple sclerosis (MS) and type 1 diabetes (TID). PLoS ONE 2009, 4(1): e4137.
63. Maier, L.M., Anderson, D.E., Severson, C.A. et al. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol 2009, 182(3): 1541-7.
64. Mondai, S., Roy, A., Pahan, K. Functional blocking monoclonal antibodies against IL-12p40 homodimer inhibit adoptive transfer of experimental allergic encephalomyelitis. J Immunol 2009, 182(8): 5013-23.
65. Skarica, M., Wang, T., McCadden, E., Kardian, D., Calabresi, P.A., Small, D., Whartenby, K.A. Signal transduction inhibition of APCs diminishes Th17 and Th1 responses in experimental autoimmune encephalomyelitis. J Immunol 2009, 182(7): 4192-9.
66. Xu, J., Drew, P.D. Peroxisome proliferator-activated receptor-gamma agonists suppress the production of IL-12 family cytokines by activated glia. J Immunol 2007, 178(3): 1904-13.
67. Judge, S.I., Smith, P.J., Stewart, P.E., Bever, C.T. Jr. Potassium channel blockers and openers as CNS neurologic therapeutic agents. Recent Pat CNS Drug Discov 2007, 2(3): 200-28.
68. Pennington, M.W., Beeton, C., Galea, C.A. et al. Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes. Mol Pharmacol 2009, 75(4): 762-73.
69. Matheu, M.P., Beeton, C., Garcia, A. et al. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity 2008, 29(4): 602-14.
70. Wulff, H., Pennington, M. Targeting effector memory T-cells with Kv1.3 blockers. Curr Opin Drug Discov Devet 2007, 10(4): 438-45.
71. Mi, S., Miller, R.H., Tang, W. et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurot 2009, 65(3): 304-15.
72. Yong, V.W. Prospects of repair in multiple sclerosis. J Neurol Sci 2009, 277(Suppl. 1): S16-8.
73. Rudick, R.A., Mi, S., Sandrock, A.W. Jr. LINGO-1 antagonists as therapy for multiple sclerosis: In vitro and in vivo evidence. Expert Opin Biol Ther 2008, 8(10): 1561-70.
74. Rosen, H, Gonzalez-Cabrera, P.J., Sanna, M.G., Brown, S. Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 2009, Epub ahead of print.
75. Mehling, M., Brinkmann, V., Antel, J. et al. FTY720 therapy exerts differential effects on T cell subsets in MS. Neurology 2008, 71(16): 1261-7.
76. Miron, V.E., Schubart, A., Antel, J.P. Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci 2008, 274(1-2): 13-7.
77. Sajad, M., Zargan, J., Chawla, R., Umar, S., Sadaqat, M., Khan, H.A. Hippocampal neurodegeneration in experimental autoimmune encephalomyelitis (EAE): Potential role of inflammation activated myeloperoxidase. Mol Cell Biochem 2009, Epub ahead of print.
78. Gray, E., Thomas, T.L., Betmouni, S., Scolding, N., Love, S. Elevated myeloperoxidase activity in white matter in multiple sclerosis. Neurosci Lett 2008, 444(2): 195-8.
79. Gray, E., Thomas, T.L., Betmouni, S., Scolding, N., Love, S. Elevated activity and microglial expression of myeloperoxidase in demyelinated cerebral cortex in multiple sclerosis. Brain Pathol 2008, 18(1): 86-95.
80. Bizzozero, O.A., Zheng, J. Identification of major S-nitrosylated proteins in murine experimental autoimmune encephalomyelitis. J Neurosci Res 2009, Epub ahead of print.
81. Fong, J.S., Rae-Grant, A., Huang, D. Neurodegeneration and neuroprotective agents in multiple sclerosis. Recent Pat CNS Drug Discov 2008, 3(3): 153-65.
82. Basso, A.S., Frenkel, D., Quintana, F.J. et al. Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Invest 2008, 118(4): 1532-43.
83. Christophi, G.P., Panos, M., Hudson, C.A. et al. Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype. Lab Invest 2009, Epub ahead of print.
84. Salinthone, S., Yadav, V., Bourdette, D.N., Carr, D.W. Lipoic acid: A novel therapeutic approach for multiple sclerosis and other chronic inflammato ry diseases of the CNS. Endocr Metab Immune Disord Drug Targets 2008, 8(2): 132-42.
85. Yan, J., Greer, J.M. NF-kappaB, a potential therapeutic target for the treatment of multiple sclerosis. CNS Neurol Disord Drug Targets 2008, 7(6): 536-57.
86. Lo, A. Advancement of therapies for neuroprotection in multiple sclerosis. Expert Rev Neurother. 2008, 8(9): 1355-66.
87. Waxman, S.G. Mechanisms of disease: Sodium channels and neuroprotection in multiple sclerosis-current status. Nat Clin Pract Neurol 2008, 4(3): 159-69.
88. Kapoor, R. Sodium channel blockers and neuroprotection in multiple sclerosis using lamotrigine. J Neurol Sci 2008, 274 (1-2): 54-6.
89. Lorz, C., Mehmet, H. The role of death receptors in neural injury. Front Biosci 2009, 14: 583-95.
90. Losonczi, E., Bencsik, K., Nagy, Z.F. et al. Tumour necrosis factor alpha gene (TNF-alpha) -376 polymorphism in Hungarian patients with primary progressive multiple sclerosis. J Neuroimmunol 2009, 208(1-2): 115-8.
91. McCoy, M.K., Tansey, M.G. TNF signaling inhibition in the CNS: Implications for normal brain function and neurodegenerative disease. J Neuroinflammation 2008, 5: 45-57.
92. Lolli, F., Tredici, G., Cavaletti, G. Pixantrone maleate. Drugs Fut 2007, 32(8): 703-6.
93. Gonsette, R.E. Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis. Expert Opin Pharmacother 2007, 8(8): 1103-16.
94. Cavaletti, G., Cavalletti, E., Crippa, L. et al. Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis. J Neuroimmunol 2004, 151(1-2): 55-65.
95. Mazzanti, B., Biagioli, T., Aldinucci, A. et al. Effects of pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis. J Neuroimmunol 2005, 168(1-2): 111-7.